Harvard turns to Evotec again to add value to early stage assets
This article was originally published in Scrip
Evotec of Germany has entered a second alliance with Harvard University in the US, this time in the field of kidney disease. Evotec's ongoing alliance with Harvard is focused on diabetes and is aimed at bolstering early stage academic assets to get them ready for out-licensing.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.